Stockscreener 앱 받기
24.54
0.73%
-0.18
전일 마감가:
$24.72
열려 있는:
$24.5
하루 거래량:
209.12K
Relative Volume:
0.15
시가총액:
$214.85M
수익:
-
순이익/손실:
$-121.02M
주가수익비율:
-2.1794
EPS:
-11.26
순현금흐름:
$-114.09M
1주 성능:
+1.36%
1개월 성능:
-11.41%
6개월 성능:
+40.31%
1년 성능:
+94.76%
1일 변동 폭
$24.27
$25.40
1주일 범위
$23.89
$25.52
52주 변동 폭
$7.31
$130.00
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Company Profile
명칭
Tonix Pharmaceuticals Holding Corp
전화
212-980-9155
주소
26 MAIN STREET, SUITE 101, CHATHAM, NY
TNXP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
24.51 | 216.69M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.07 | 104.83B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
608.38 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.35 | 60.43B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
793.85 | 48.45B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
337.51 | 37.91B | 4.56B | -176.77M | 225.30M | -1.7177 |
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-04-18 | 개시 | Noble Capital Markets | Outperform |
| 2019-04-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2017-08-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2016-09-07 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 재확인 | Oppenheimer | Outperform |
| 2015-11-04 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-12 | 개시 | Oppenheimer | Outperform |
| 2015-02-17 | 재확인 | ROTH Capital | Buy |
| 2014-09-29 | 재확인 | ROTH Capital | Buy |
모두보기
토닉스 파마슈티컬스 홀딩 주식(TNXP)의 최신 뉴스
What data driven models say about Tonix Pharmaceuticals Holding Corp.’s futurePortfolio Return Report & Real-Time Buy Zone Alerts - newser.com
Custom watchlist performance reports with Tonix Pharmaceuticals Holding Corp. - newser.com
Is Tonix Pharmaceuticals Holding Corp. trending in predictive chart modelsTrade Volume Summary & High Conviction Buy Zone Alerts - newser.com
Detecting price anomalies in Tonix Pharmaceuticals Holding Corp. with AIWeekly Loss Report & Free Fast Gain Swing Trade Alerts - newser.com
Tonix Pharma Appoints New Head of Market Access - MSN
How Tonix Pharmaceuticals Holding Corp. stock performs after earningsTrend Reversal & Free Safe Capital Growth Stock Tips - newser.com
Tonix Pharmaceuticals appoints Ganesh Kamath as head of market access By Investing.com - Investing.com Nigeria
Acadia’s Prader-Willi miss gives Tonix a chance at the market - BioCentury
Tonix Pharmaceuticals Advances TNX-2900 for Prader-Willi Syndrome to Phase 2 Clinical Trial - citybuzz -
Tonix Pharmaceuticals Further Strengthens Commercial - GlobeNewswire
Tonix Pharmaceuticals Appoints Ganesh Kamath as Head of Market Access - citybiz
Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain? - PharmaVoice
Tonix Pharmaceuticals appoints Ganesh Kamath as head of market access - Investing.com
Tonix Pharmaceuticals Holding Corp. Appoints Ganesh Kamath as Head of Market Access, Effective September 29, 2025 - MarketScreener
Tonix to begin phase 2 trial of PWS treatment with orphan status - Investing.com Nigeria
Tonix Pharmaceuticals (TNXP) Advances TNX-2900 for Prader-Willi Syndrome Treatment - GuruFocus
Tonix Pharmaceuticals to Evaluate TNX-2900 for Prader-Willi Syndrome in Phase 2 Trial - MarketScreener
Tonix Pharma Advances TNX-2900 to Phase 2 Trial - TipRanks
Tonix Pharmaceuticals Plans to Initiate Prader-Willi - GlobeNewswire
Tonix Pharmaceuticals plans to initiate Prader-Willi syndrome phase 2 trial of TNX-2900 in 2026 - MarketScreener
Tonix Pharmaceuticals Initiates Phase 2 Trial for TNX-2900 in Children with Prader-Willi Syndrome Following FDA Clearance and Orphan Drug Designation - Quiver Quantitative
Potential Breakthrough for Fatal Childhood Obesity: Tonix's New Drug Targets 30-Year Life Expectancy Crisis - Stock Titan
Is Tonix Pharmaceuticals Holding Corp a good long term investmentMomentum Trading Signals & Connect With Bulls, Avoid the Bears - earlytimes.in
13,670 Shares in Tonix Pharmaceuticals Holding Corp. $TNXP Purchased by Rhumbline Advisers - MarketBeat
Tonix advances TNX-102 SL for depression after positive FDA meeting boosts development path - Proactive financial news
What is Zacks Small Cap's Estimate for TNXP FY2025 Earnings? - MarketBeat
Tonix Pharma Licenses Rights to Lyme Disease Antibody - MSN
Daily Brief Health Care: Shandong Weigao Blood Purification Products, TYK Medicines, Butong Group, Alteogen Inc, SBC Medical Group Holdings , Achieve Life Sciences , Tonix Pharmaceuticals Holding and more - Smartkarma
Tonix gains global rights to TNX-4800, developing one-dose seasonal protection for Lyme disease - Proactive financial news
TNXP: Tonmya™ Approved by FDA… - Zacks Small Cap Research
Tonix Pharmaceuticals Holding Corp.(NasdaqCM: TNXP) added to S&P Global BMI Index - MarketScreener
Tonix plans IND filing for depression treatment after FDA meeting By Investing.com - Investing.com Nigeria
Analyst Downgrade: Is now the right time to enter Tonix Pharmaceuticals Holding CorpWeekly Risk Report & Low Drawdown Investment Strategies - خودرو بانک
Tonix plans IND filing for depression treatment after FDA meeting - Investing.com India
Tonix Pharma Completes FDA Meeting for TNX-102 SL - TipRanks
Fed Watch: Can LeddarTech Holdings Inc Equity Warrant navigate macro headwindsQuarterly Risk Review & Low Risk Entry Point Tips - خودرو بانک
Tonix Pharmaceuticals (TNXP) Advances Toward New Depression Trea - GuruFocus
토닉스 파마슈티컬스 홀딩 (TNXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.85%
2.05%
자본화:
|
볼륨(24시간):